Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing
Source: SeekingAlpha
2026-05-12 21:52:14 ET
More on Lineage Cell Therapeutics
- Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
- Lineage Cell Therapeutics, Inc. (LCTX) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow
- Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
- Lineage Cell Therapeutics GAAP EPS of -$0.03 misses by $0.01, revenue of $1.72M misses by $1.36M
- Lineage Cell Therapeutics Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing
Lineage Cell Therapeutics, Inc.
NASDAQ: LCTX
LCTX Trading
-5.17% G/L:
$1.10 Last:
1,736,292 Volume:
$1.15 Open:
LCTX Latest News
July 06, 2026 08:00:00 am
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
May 12, 2026 04:01:00 pm
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
$424,954,306
168,599,757
0.11%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
Carlsbad
